AR and breast carcinoma: However, a recent ChIP-seq study of ER binding sites demonstrated that treatment of MCF-7 breast cancer cells with the AR antagonist enzalutamide decreased the number of E2-induced ER genomic binding sites by 50%, implicating a role for AR in ER genomic binding [21].